- Home
- IMUX vs PROP Comparison
IMUX vs PROP Comparison
Compare IMUX & PROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- PROP
- Stock Information
- Founded
- IMUX 2016
- PROP 2001
- Country
- IMUX United States
- PROP United States
- Employees
- IMUX N/A
- PROP N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- PROP Investment Bankers/Brokers/Service
- Sector
- IMUX Health Care
- PROP Finance
- Exchange
- IMUX Nasdaq
- PROP Nasdaq
- Market Cap
- IMUX 92.2M
- PROP 99.8M
- IPO Year
- IMUX N/A
- PROP N/A
- Fundamental
- Price
- IMUX $0.72
- PROP $1.93
- Analyst Decision
- IMUX Strong Buy
- PROP Buy
- Analyst Count
- IMUX 5
- PROP 5
- Target Price
- IMUX $7.00
- PROP $6.75
- AVG Volume (30 Days)
- IMUX 1.4M
- PROP 1.7M
- Earning Date
- IMUX 11-06-2025
- PROP 11-14-2025
- Dividend Yield
- IMUX N/A
- PROP N/A
- EPS Growth
- IMUX N/A
- PROP N/A
- EPS
- IMUX N/A
- PROP N/A
- Revenue
- IMUX N/A
- PROP $88,854,000.00
- Revenue This Year
- IMUX N/A
- PROP $4,131.26
- Revenue Next Year
- IMUX N/A
- PROP $69.50
- P/E Ratio
- IMUX N/A
- PROP N/A
- Revenue Growth
- IMUX N/A
- PROP N/A
- 52 Week Low
- IMUX $0.56
- PROP $1.64
- 52 Week High
- IMUX $1.42
- PROP $10.58
- Technical
- Relative Strength Index (RSI)
- IMUX 37.43
- PROP 48.31
- Support Level
- IMUX $0.67
- PROP $1.81
- Resistance Level
- IMUX $0.87
- PROP $1.93
- Average True Range (ATR)
- IMUX 0.05
- PROP 0.15
- MACD
- IMUX -0.01
- PROP 0.01
- Stochastic Oscillator
- IMUX 21.92
- PROP 40.00
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.